Federico Cappuzzo
Federico Cappuzzo
Istituto Nazionale Tumori Regina Elena, Roma, Italy
Verified email at ifo.gov.it
Title
Cited by
Cited by
Year
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ...
science 316 (5827), 1039-1043, 2007
47272007
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
25692014
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
21502010
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer
F Cappuzzo, FR Hirsch, E Rossi, S Bartolini, GL Ceresoli, L Bemis, ...
Journal of the National Cancer Institute 97 (9), 643-655, 2005
18662005
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...
New England Journal of Medicine 378 (24), 2288-2301, 2018
15002018
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
14922017
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, ...
The lancet oncology 11 (6), 521-529, 2010
14812010
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase …
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The lancet oncology 16 (3), 257-265, 2015
12572015
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ...
Nature genetics 44 (10), 1104-1110, 2012
10482012
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy …
EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ...
The Lancet 384 (9944), 665-673, 2014
9762014
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ...
Science translational medicine 2 (62), 62ra93-62ra93, 2010
8572010
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ...
Science translational medicine 3 (99), 99ra86-99ra86, 2011
5432011
Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients
F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ...
Journal of clinical oncology 27 (10), 1667, 2009
5302009
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A D'incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, ...
British journal of cancer 112 (1), 95-102, 2015
4692015
Akt phosphorylation and gefitinib efficacy in patients with advanced non–small-cell lung cancer
F Cappuzzo, E Magrini, GL Ceresoli, S Bartolini, E Rossi, V Ludovini, ...
Journal of the National Cancer Institute 96 (15), 1133-1141, 2004
4452004
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor–positive non–small-cell lung cancer patients
F Cappuzzo, M Varella-Garcia, H Shigematsu, I Domenichini, S Bartolini, ...
Journal of clinical oncology 23 (22), 5007-5018, 2005
4422005
Identifying and targeting ROS1 gene fusions in non–small cell lung cancer
KD Davies, AT Le, MF Theodoro, MC Skokan, DL Aisner, EM Berge, ...
Clinical Cancer Research 18 (17), 4570-4579, 2012
4182012
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
GL Ceresoli, F Cappuzzo, V Gregorc, S Bartolini, L Crino, E Villa
Annals of Oncology 15 (7), 1042-1047, 2004
3972004
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small …
H West, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ...
The Lancet Oncology 20 (7), 924-937, 2019
3602019
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
FR Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, AC Xavier, ...
Annals of Oncology 18 (4), 752-760, 2007
3392007
The system can't perform the operation now. Try again later.
Articles 1–20